

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	To Be Assigned (U.S. Natl. Phase of PCT/EP2004/005208; Int'l Filing Date: May 14, 2004)
				First Named Inventor	Bachmann <i>et al.</i>
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	1700.0420001/BJD/SJE

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL1	Bachmann, M.F. and Zinkernagel, R.M., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science Publishers (1996)	
	NPL2	Benhar, I., "Biotechnological applications of phage and cell display," <i>Biotechnol. Adv.</i> 19:1-33, Elsevier Science Inc. (2001)	
	NPL3	Fehr, T., <i>et al.</i> , "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci. USA</i> 95:9477-9481, National Academy of Sciences (1998)	
	NPL4	Jegerlehner, A., <i>et al.</i> , "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20:3104-3112, Elsevier Science Ltd. (August, 2002)	
	NPL5	Vasiljeva, I., <i>et al.</i> , "Mosaic Q $\beta$ coats as a new presentation model," <i>FEBS Lett.</i> 431:7-11, Federation of European Biochemical Societies (1998)	
	NPL6	Weitkamp, J.-H., <i>et al.</i> , "Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles," <i>J. Immunol. Meth.</i> 275:223-237, Elsevier Science B.V. (April, 2003)	

Examiner Signature	/David Saunders/	Date Considered	03/29/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.S./